quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 16, 2026

Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider

View original at globenewswire.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Surgical Procedures dominated with 38.45% market share in 2025

    80% confidence
  • Submucosal Fibroids dominated with 36.24% market share in 2025

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Laparoscopic Surgery dominated with 36.58% in 2025 due to its widespread adoption, proven safety, and effectiveness

    80% confidence
  • Minimally invasive techniques, including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound, have seen adoption rates rise by more than 60% in the past five years

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033

    80% confidence
  • Minimally invasive techniques including laparoscopic myomectomy, uterine artery embolization, and MRI-guided focused ultrasound have seen adoption rates rise by more than 60% in the past five years

    80% confidence
  • The Uterine Fibroid Market will grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence
  • Hospitals & Clinics dominated with 47.49% market share in 2025

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • Intramural Fibroids is expected to grow at the fastest CAGR of 8.20% from 2026 to 2033

    80% confidence
  • The Uterine Fibroid Market size was valued at USD 5.26 Billion in 2025 and is projected to reach USD 9.43 Billion by 2033 and grow at a CAGR of 7.63% over the forecast period 2026-2033

    80% confidence
  • North America is predicted to hold a 45.32% market share in 2025 for uterine fibroids

    80% confidence
  • Hospitals & Clinics dominated with 47.49% in 2025 due to their advanced infrastructure and specialized care

    80% confidence
  • Minimally Invasive Procedures is expected to grow at the fastest CAGR of 8.63% from 2026 to 2033

    80% confidence
  • Healthcare expenditures in developing regions have grown by an approximate 45% over the last decade

    80% confidence
  • Asia Pacific is expected to grow at the fastest CAGR from 2026-2033 in the Uterine Fibroid Market

    80% confidence
  • MRI-Guided Focused Ultrasound expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • Ambulatory Surgical Centers is expected to grow at the fastest CAGR of 8.43% from 2026 to 2033

    80% confidence
  • Uterine fibroids occur in approximately 70 to 80% of women by the age of 50

    80% confidence
  • MRI-Guided Focused Ultrasound (MRgFUS) is expected to grow at the fastest CAGR of 8.83% from 2026 to 2033

    80% confidence
  • The U.S. Uterine Fibroid Market size was valued at USD 1.78 Billion in 2025 and is projected to reach USD 3.11 Billion by 2033, growing at a CAGR of 7.25%

    80% confidence
  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence
  • Submucosal Fibroids dominated with 36.24% market share in 2025

    80% confidence
  • Laparoscopic Surgery dominated with 36.58% market share in 2025

    80% confidence
  • Submucosal Fibroids dominated with 36.24% in 2025 due to their high prevalence and significant symptom severity

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Uterine Fibroid Market Size to Reach USD 9.43 Billion by 2033 with 7.63% CAGR – SNS Insider — Source | Via News | pt.VIA.NEWS